{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:59:08Z","timestamp":1789448348465,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.eururo.2006.05.011","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T17:13:22Z","timestamp":1149700402000},"page":"1032-1039","source":"Crossref","is-referenced-by-count":74,"title":["Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor"],"prefix":"10.1016","volume":"50","author":[{"given":"Ugo","family":"De Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Testore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Burattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zumaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Marangolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2006.05.011_bib1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2005.06.019","article-title":"Guidelines on testicular cancer","volume":"48","author":"Albers","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.05.011_bib2","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<848::AID-IJC29>3.0.CO;2-#","article-title":"Treatment of patients with cisplatin-refractory testicular germ-cell cancer","volume":"83","author":"Bokemeyer","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib4","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2003.06.067","article-title":"Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables","volume":"21","author":"Vaena","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib5","first-page":"95","article-title":"The status of high-dose chemotherapy with hematopoietic stem cell transplantation in patients with germ cell tumor","volume":"87","author":"De Giorgi","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.eururo.2006.05.011_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1381::AID-CNCR23>3.0.CO;2-1","article-title":"A phase II trial of paclitaxel in refractory germ cell tumors","volume":"82","author":"Sandler","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","article-title":"Phase II trial of gemcitabine in refractory germ cell tumors","volume":"17","author":"Einhorn","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","article-title":"Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer","volume":"17","author":"Bokemeyer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib10","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors: a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s004320050338","article-title":"Antitumoral activity of oxaliplatin\/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients","volume":"125","author":"Souli\u00e9","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib12","first-page":"194a","article-title":"Paclitaxel, cisplatin, gemcitabine (TPG) third line therapy in metastatic germ cell tumors of the testis","volume":"20","author":"Pizzocaro","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.eururo.2006.05.011_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.eururo.2005.04.024","article-title":"Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors","volume":"48","author":"Farmakis","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.05.011_bib16","first-page":"389","article-title":"A phase II multicentre study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT)","volume":"22","author":"Theodore","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.coc.0000128727.40450.9e","article-title":"Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: preliminary experience","volume":"27","author":"De Giorgi","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<831::AID-IJC24>3.0.CO;2-O","article-title":"Management of intermediate prognosis germ cell cancer. Results of a phase I-II study of taxol-BEP","volume":"83","author":"de Wit","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","article-title":"A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-PEB) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial","volume":"93","author":"Mead","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2006.05.011_bib22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bjc.66000524","article-title":"Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"87","author":"Kollmannsberger","year":"2002","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib23","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/sj.bjc.6601176","article-title":"Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"89","author":"Powles","year":"2002","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.eururo.2006.05.011_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eururo.2004.03.001","article-title":"Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ cell tumor patients: a phase II study","volume":"46","author":"Pectasides","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2006.05.011_bib25","first-page":"395","article-title":"A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors","volume":"23","author":"Bedano","year":"2005","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806005781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283806005781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T03:25:17Z","timestamp":1555644317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283806005781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0302283806005781"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2006.05.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}